TOKYO -- Japan's Daiichi Sankyo will invest 90 billion yen ($590 million) in a domestic facility to research next-generation drugs, as Prime Minister Sanae Takaichi looks to build up the country's biopharmaceutical development as an economic security measure.
Pharmaceuticals
Daiichi Sankyo to spend $600m to keep drug discovery in Japan
R&D center for next-generation treatments aligns with PM Takaichi's economic security push
Daiichi Sankyo is concentrating drug development in its home country of Japan. (Daiichi Sankyo)
Read Next
Latest on Pharmaceuticals
